TMCnet News
Research and Markets: Kyowa Hakko Kirin's Nouriast for Parkinson's Disease - Forecast and Market Analysis to 2022DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/xd3gfg/nouriast) has announced the addition of the "Nouriast (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering. Istradefylline is a first-in-class adenosine A2 receptor inhibitor, marketed in Japan under the brand name Nouriast by Kyowa Hakko Kirin. It was approved in Japan for adjunct use with levodopa in advanced-stage patients with wearing-off in March 2013, and launched in May 2013 (Kyowa Hakko Kirin, press release, March 25, 2013; Kyowa Hakko Kirin, press release, May 29, 2013). Scope
Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Nouriast (istradefylline) 7 Appendix For more information visit http://www.researchandmarkets.com/research/xd3gfg/nouriast
|